Genmab — Juli 2017

[JKY_VH]

NBI +1,39%, det må godt smitte af i morgen.

[dohk]

U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.
https://finance.yahoo.com/news/fda-puts-hold-merck-multiple-213905828.html

[dohk]

ser ikke ud til Pd1 inhibitorer får en plads en i behandling af MM

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[JKY_VH]

God morgen:-)

[E_L]

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers http://ir.celgene.com/releasedetail.cfm?ReleaseID=1032240

[GeorgeBest]

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC MUTANOME http://www.4-traders.com/news/Nature-Publication-Reports-Favorable-Clinical-Trial-Results-of-BioNTech-s-Individualized-Cancer-Vacc--24703913/

[bibob]

That doesn't have anything to doo with Genmab, - has it. ?? E L.

[E_L]

no, not directly, just wanted to show there are still plenty companies thinking PD1 inhibitor
is usefull

[Bulder]

Vi har vel heller ikke hørt dårligt (endnu) om nivolumab, som kører i et kombistudie med dara i bl.a. MM?

[Bulder]

Kunne det tænkes at problemet ligger specifikt i Keytruda?

[E_L]

sure, or or maybe even Keytruda in that specific combo only. time will tell.

[Jedi]

I agree. The current problems of Keytruda are limited to MM. All Keytruda trials outside MM continue at full speed and PD-1 / PD-L1 agents are still considered very successful in solid tumors

[Jedi]

The new Celgene collaboration on PD-1 is also targeting solid tumors and not MM

[Bulder]

Ingen tvivl om at PD-1 kører ufortrødent videre i solide tumorer. Så må vi vente og se om Opdivo (sammen med dara) giver problemer i MM.

[Jedi]

Det kunne jo også være kombinationen af PD-1 og en Imid (Revlimid/Pomalyst) som giver en uheldig bivirkning i MM, mens Dara + PD-1 virker ok, det kan vi håbe på - det bliver spændende at følge

[E_L]

NICE : Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Technology appraisal [TA454] Published date: 05 July 2017
https://www.nice.org.uk/guidance/ta454

[E_L]

this is as expected, Janssen had withdrawn this application

[E_L]

we wati for this Daratumumab for multiple myeloma [ID933] In development [GID-TA10076] Expected publication date: 26 July 2017